NO951772L - Process for the preparation of taxane derivatives, the thus obtained new taxanes as well as anti-tumor and anti-leukemia preparations containing the taxanes - Google Patents

Process for the preparation of taxane derivatives, the thus obtained new taxanes as well as anti-tumor and anti-leukemia preparations containing the taxanes

Info

Publication number
NO951772L
NO951772L NO951772A NO951772A NO951772L NO 951772 L NO951772 L NO 951772L NO 951772 A NO951772 A NO 951772A NO 951772 A NO951772 A NO 951772A NO 951772 L NO951772 L NO 951772L
Authority
NO
Norway
Prior art keywords
residue
taxanes
general formula
tumor
leukemia
Prior art date
Application number
NO951772A
Other languages
Norwegian (no)
Other versions
NO951772D0 (en
Inventor
Jean-Dominique Bourzat
Alain Commercon
Dominique Deprez
Jean-Pierre Pulicani
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO951772D0 publication Critical patent/NO951772D0/en
Publication of NO951772L publication Critical patent/NO951772L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B3/00—Electrolytic production of organic compounds
    • C25B3/20—Processes
    • C25B3/25—Reduction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B11/00—Electrodes; Manufacture thereof not otherwise provided for
    • C25B11/04—Electrodes; Manufacture thereof not otherwise provided for characterised by the material
    • C25B11/042—Electrodes formed of a single material
    • C25B11/046—Alloys
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25B—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES FOR THE PRODUCTION OF COMPOUNDS OR NON-METALS; APPARATUS THEREFOR
    • C25B9/00—Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
    • C25B9/17—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof
    • C25B9/19—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms
    • C25B9/23—Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Metallurgy (AREA)
  • Electrochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Electrolytic Production Of Non-Metals, Compounds, Apparatuses Therefor (AREA)

Abstract

En fremgangsmåte for fremstilling av taxanderlvater med den generelle formel (I): der R betyr et hydrogenatom eller en acetyl- eller alkoksyacetylrest, et av symbolene R^ og R2 betyr et hydrogenatom og den andre betyr en hydroksyrest, R3 betyr et hydrogenatom eller en rest med den generelle formel (II): R4-NH R-,-0" HO OCOCH- Ar HO ococ6H5 der Ar betyr en arylrest og R4 betyr en benzoylrest eller en rest Rs-O-CO-, der RS betyr en alkyl-, alkenyl-, cykloalkyl-, cykloalkenyl, blcykloalkyl-, fenyl eller heterocyklylrest, på elektrokjemisk måte fra et taxan- derlvat med den generelle formel (III): der substltuentene har den ovenfor angitte betydning. R-0 -K2 R-,-0" Farmasøytiske preparater som Inneholder en ny forbindelse med den generelle formel (I) der R3 betyr en rest med den generelle formel (II), oppviser Interessante antltumorale og antlleukemlske egenskaper.A process for preparing taxane derivatives of general formula (I): wherein R represents a hydrogen atom or an acetyl or alkoxyacetyl residue, one of the symbols R 1 and R 2 represents a hydrogen atom and the other means a hydroxy residue, R 3 means a hydrogen atom or a residue with the general formula (II): R 4 -NH R -, - 0 "HO OCOCH-Ar HO ococ6H5 wherein Ar represents an aryl residue and R4 represents a benzoyl residue or a residue R alkenyl, cycloalkyl, cycloalkenyl, bicycloalkyl, phenyl or heterocyclyl residue, electrochemically from a taxane derivative of the general formula (III): wherein the substituents have the meaning given above. R-O-K2 R Pharmaceutical compositions containing a novel compound of general formula (I) wherein R3 represents a residue of general formula (II) exhibit interesting anti-tumor and anti-leukemic properties.

NO951772A 1992-11-12 1995-05-05 Process for the preparation of taxane derivatives, the thus obtained new taxanes as well as anti-tumor and anti-leukemia preparations containing the taxanes NO951772L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9213586A FR2697841B1 (en) 1992-11-12 1992-11-12 New taxane derivatives, their preparation and the pharmaceutical compositions containing them.
PCT/FR1993/001102 WO1994011547A1 (en) 1992-11-12 1993-11-10 Process for the preparation of taxane derivatives, novel taxanes so obtained and antitumour and antileukaemia compositions containing same

Publications (2)

Publication Number Publication Date
NO951772D0 NO951772D0 (en) 1995-05-05
NO951772L true NO951772L (en) 1995-05-05

Family

ID=9435452

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951772A NO951772L (en) 1992-11-12 1995-05-05 Process for the preparation of taxane derivatives, the thus obtained new taxanes as well as anti-tumor and anti-leukemia preparations containing the taxanes

Country Status (15)

Country Link
EP (1) EP0667922A1 (en)
JP (1) JPH08503261A (en)
KR (1) KR950704540A (en)
AU (1) AU5425794A (en)
CA (1) CA2149240A1 (en)
CZ (1) CZ122495A3 (en)
FI (1) FI952294A (en)
FR (1) FR2697841B1 (en)
MX (1) MX9306883A (en)
NO (1) NO951772L (en)
PL (1) PL308957A1 (en)
RU (1) RU95112464A (en)
SK (1) SK60895A3 (en)
WO (1) WO1994011547A1 (en)
ZA (1) ZA938366B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2710642B1 (en) * 1993-09-29 1995-11-17 Rhone Poulenc Rorer Sa New taxoids, their preparation and the pharmaceutical compositions containing them.
FR2711369B1 (en) * 1993-10-20 1995-11-17 Rhone Poulenc Rorer Sa New taxoids, their preparation and the compositions containing them.
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
EP0914116B1 (en) * 1996-05-22 2000-10-11 Protarga Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and taxotere
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
KR101535395B1 (en) * 2004-01-22 2015-07-08 유니버시티 오브 마이애미 Topical co-enzyme q10 formulations and methodns of use
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EA201101519A1 (en) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи METHODS OF DIAGNOSTICS OF METABOLIC DISTURBANCES USING EPIMETABOLIC SWITCHES, MULTIPLE-DIFFERENT INTRACELLULAR MOLECULES OR IMPACT FACTORS
JP6092844B2 (en) 2011-04-04 2017-03-08 バーグ エルエルシー Treatment of central nervous system tumors
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
BR112015025424A2 (en) 2013-04-08 2017-07-18 Berg Llc cancer treatment using coenzyme q10 combination therapies
JP6595478B2 (en) 2013-09-04 2019-10-23 バーグ エルエルシー Cancer treatment by continuous injection of coenzyme Q10

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
AU5425794A (en) 1994-06-08
ZA938366B (en) 1994-06-13
MX9306883A (en) 1995-01-31
SK60895A3 (en) 1996-03-06
WO1994011547A1 (en) 1994-05-26
EP0667922A1 (en) 1995-08-23
KR950704540A (en) 1995-11-20
NO951772D0 (en) 1995-05-05
FI952294A0 (en) 1995-05-11
FR2697841B1 (en) 1995-01-13
JPH08503261A (en) 1996-04-09
RU95112464A (en) 1997-02-20
CZ122495A3 (en) 1995-12-13
CA2149240A1 (en) 1994-05-26
FI952294A (en) 1995-05-11
FR2697841A1 (en) 1994-05-13
PL308957A1 (en) 1995-09-04

Similar Documents

Publication Publication Date Title
NO951772L (en) Process for the preparation of taxane derivatives, the thus obtained new taxanes as well as anti-tumor and anti-leukemia preparations containing the taxanes
BR9307613A (en) New taxoids process of preparing a taxoid and pharmaceutical composition
AU2212392A (en) Novel alkoxy substituted taxanes and pharmaceutical compositions containing them
AU2212292A (en) Novel furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
EP0356214A3 (en) Thiazolidine dione derivatives
NO951283L (en) New taxane derivatives, their preparation as well as pharmaceutical preparations containing the derivatives
PL310441A1 (en) Novel taxoides, method of obtaining them and pharmaceutical compositions containing such compounds
TW427988B (en) Process for the preparation of taxane derivatives
HUT41713A (en) Process for production of //arol-cyclobutyl/ alkyl/-amins and medical preparatives containing thereof
NO974563L (en) New taxoids, their preparation as well as pharmaceutical preparations containing the compounds
IL81733A0 (en) Penem derivatives,their preparation and pharmaceutical compositions containing them
MX9604465A (en) Process for the preparation of 7-hydroxy taxanes.